In HER2-positive gastric cancer, trastuzumab in combination with chemotherapy leads to an increase in overall survival compared to chemotherapy alone (Gong et al. 2016; Ryu et al. 2015; Soularue et al. 2015; Thuss-Patience et al. 2017). Here, ERBB2 is linked to gastric cancer.